Influence of genetic polymorphism of donor CYP3A5 on FK506 individual dosage regimen in liver transplantation recipients

Chinese Pharmaceutical Journal

Volumn 42, Issue 4, 2007, Pages 314-317

  Yu, Song Feng ^a   Wu, Li Hua ^a   Jin, Jing ^a   Yan, Sheng ^a   Xie, Hai Yang ^a   Gao, Jin Ting ^a   Zheng, Shu Sen ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

CYP3A5; Genetic polymorphism; Liver transplantation; Tacrolimus

Indexed keywords

CYTOCHROME P450 3A5; TACROLIMUS;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DNA SEQUENCE; DOSE RESPONSE; DRUG BLOOD LEVEL; GENETIC POLYMORPHISM; GENOTYPE; GRAFT VERSUS HOST REACTION; HUMAN; LIVER TRANSPLANTATION; ORGAN DONOR; RECIPIENT; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; TREATMENT DURATION;

EID: 34547772634     PISSN: 10012494     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. DENTON M D, MAGEE C C, SAYEGH M H. Immunosuppressive strategies in transplantation[J]. Lancet, 1999,353(9158):1083-1091.
2. EVANS W E, RELLING, M V. Pharmacogenomics: translating functional genomics into rational therapeutics[J]. Science, 1999,286(5439):487-491.
3. VENKATARAMANAN R, SWAMINATHAN A, PRASAD T, et al. Clinical pharmacokinetics of tacrolimus[J]. Clin Pharmacokinet, 1995,29(6):404-430.
4. ANDREWS P A, SEN M, CHANG R W. Racial variation in dosage requirements of tacrolimus[J]. Lancet, 1996,348(9039):1446.
5. THERVET E, ANGLICHEAU D, KING B, et al. Impact of cytochrome P450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients[J]. Transplantation, 2003,76(8):1233-1235.
6. FINTA C, ZAPHIROPOULOS P G. The human cytochrome P450 3A locus. Gene evolution by capture of downstream exons[J]. Gene, 2000,260(1-2):13-23.
7. KUEHL P, ZHANG J, LIN Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression[J]. Nat Genet, 2001,27(4):383-391.
8. HUSTERT E, HABERL M, BURK O, et al. The genetic determinants of the CYP3A5 polymorphism[J]. Pharmacogenetics, 2001,11(9):773-779.
9. MACPHEE I A, FREDERICKS S, MOHAMED M, et al. Tacrolimus pharmacogenetics: the CYP3A5 *1 allele predicts low dose-normalized tacrolimus blood concentrations in whites and South Asians[J]. Transplantation, 2005,79(4):499-502.
10. ZHENG H, WEBBER S, ZEEVI A, et al. Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 and MDR1 gene polymorphisms[J]. Am J Transplant, 2003,3(4):477-483.
11. ZHENG H, ZEEVI A, SCHUETZ E, et al. Tacrolimus dosing in adult lung transplant patients is related to cytochrome P4503A5 gene polymorphism[J]. J Clin Pharmacol, 2004,44(2):135-140. (fefjSgjCj:2005-12-11)